← Leaderboards
Robert Scott Svatek
University Of Texas Hlth Science Center
$2,973,815
Attributed
$2,973,815
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $486.5K · FY2014–24$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,973,815 · 2
By mechanism
R01$2,299,895 · 1
K23$673,920 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Science Center
Same institution · by research overlap
- Andrew Jacob Brenner$6,506,512
- Dipen Parekh$3,113,769
- Heather Graham Hambright$283,182
- Josephine A Taverna$1,600,331
- Neelam Mukherjee$778,615
Others in their field
Top investigators on “Relapse”
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Charles A Coltman · Southwest Oncology Group$124,514,512
- Mary M Horowitz · Medical College Of Wisconsin$85,160,686
- Monica M Bertagnolli · Strang Cancer Prevention Center$41,995,734
- Effie W Petersdorf · Fred Hutchinson Cancer Research Center$29,676,600
- Misty Ward Stevens · Intervexion Therapeutics, Llc$28,867,910
Research focus
RelapseResponseMonitorMediatingProceduresPreventExcisionImmunityInsightMalignant NeoplasmsMtor InhibitorMtor InhibitionNeoplastic CellNovel StrategiesDiagnosisBladderImmuneBladder NeoplasmAutologousImmunotherapyAntigensMalignant Neoplasm Of Urinary BladderCancer ImmunotherapySirolimus
Grant awards (9)
eRapa for bladder cancer prevention$431,224
R01 · FY2024 · CA · contact PI
eRapa for bladder cancer prevention$476,606
R01 · FY2023 · CA · contact PI
eRapa for bladder cancer prevention$448,412
R01 · FY2022 · CA · contact PI
eRapa for bladder cancer prevention$457,121
R01 · FY2021 · CA · contact PI
eRapa for bladder cancer prevention$486,532
R01 · FY2020 · CA · contact PI
Improving immunotherapy in bladder cancer by targeting immune dysfunction$168,480
K23 · FY2017 · CA · contact PI
Improving immunotherapy in bladder cancer by targeting immune dysfunction$168,480
K23 · FY2016 · CA · contact PI
Improving immunotherapy in bladder cancer by targeting immune dysfunction$168,480
K23 · FY2015 · CA · contact PI
Improving immunotherapy in bladder cancer by targeting immune dysfunction$168,480
K23 · FY2014 · CA · contact PI